Biopharma manufacturing company Repligen Corporation (NASDAQ: RGEN) will be reporting results this Tuesday morning. Here’s what you need to know.
Repligen beat analysts’ revenue expectations last quarter, reporting revenues of $194.3 million, up 14.8% year on year. It was a strong quarter for the company, with a beat of analysts’ EPS estimates and a solid beat of analysts’ full-year EPS guidance estimates.
Is Repligen a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Repligen’s revenue to grow 10.7% year on year, slowing from the 14.8% increase it recorded in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Repligen rarely misses Wall Street’s revenue estimates.
Looking at Repligen’s peers in the life sciences tools & services segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Medpace delivered year-on-year revenue growth of 17.2%, beating analysts’ expectations by 2.6%, and West Pharmaceutical Services reported revenues up 13.8%, topping estimates by 3.5%. Medpace traded up 14.7% following the results while West Pharmaceutical Services was down 8.6%.
Read our full analysis of Medpace’s results here and West Pharmaceutical Services’s results here.
Investors in the life sciences tools & services segment have had steady hands going into earnings, with share prices up 1.3% on average over the last month. Repligen is down 3.6% during the same time and is heading into earnings with an average analyst price target of $178.05 (compared to the current share price of $131.96).
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.
